Diabetic Neuropathy Drugs Market by Product, and Geography - Forecast and Analysis 2021-2025
- Published: Jan 2022
- Pages: 120
- SKU: IRTNTR72073
Enjoy complimentary customisation on priority with our Enterprise License!
One user only.
Quick & easy download option
Unlimited user access (Within your organization)
Complimentary Customization Included
The diabetic neuropathy drugs market share is expected to increase by USD 2.37 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 12.20%.
This diabetic neuropathy drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers diabetic neuropathy drugs market segmentation by product (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others) and geography (North America, Europe, Asia, and ROW). The diabetic neuropathy drugs market report also offers information on several market vendors, including Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, and Pfizer Inc. among others.
What will the Diabetic Neuropathy Drugs Market Size be During the Forecast Period?
Download the Free Report Sample to Unlock the Diabetic Neuropathy Drugs Market Size for the Forecast Period and Other Important Statistics
Diabetic Neuropathy Drugs Market: Key Drivers, Trends, and Challenges
The increasing prevalence of diabetic neuropathy is notably driving the diabetic neuropathy drugs market growth, although factors such as the high cost of treatment may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the diabetic neuropathy drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Diabetic Neuropathy Drugs Market Driver
The increasing prevalence of diabetic neuropathy is one of the key drivers supporting the diabetic neuropathy drugs market growth. Diabetic neuropathy often damages nerves in the feet and legs of an individual. The prevalence of diabetic neuropathy has increased due to the rise in the prevalence of diabetes globally. according to the CDC, in 2021, 50% of people with diabetes had some form of nerve damage. The longer a person has diabetes, the higher is the risk of developing neuropathy. About one-third to one-half of people with diabetes have peripheral neuropathy. About 60%-70% of people with diabetes develop diabetic neuropathy. Thus, such an increase in the number of diabetic neuropathy is driving the market growth.
Key Diabetic Neuropathy Drugs Market Trend
The development of topical patches for the treatment of diabetic neuropathy is another factor supporting the diabetic neuropathy drugs market growth. The traditional approaches for the treatment of neuropathic pain associated with diabetic neuropathy led to many complications, which affected patient compliance. Topical treatments are considered an effective way to treat chronic pain as the current treatments have limited absorption. Also, topical treatments are safer than systemic treatment options. For instance, 5% of topical lidocaine applied as a patch can treat diabetic neuropathy. In May 2009, Qutenza was approved for the treatment of non-diabetic adults with peripheral neuropathy and in September 2015, the license of the drug included diabetic patients as well. Such a rapid increase in the development of tropical patches for the treatment is driving the market growth.
Key Diabetic Neuropathy Drugs Market Challenge
The high cost of treatment is hindering the diabetic neuropathy drugs market growth. The treatment costs of diabetic peripheral neuropathy and its complications can range between $4.6 billion and $13.7 billion in the US annually. As of now, only symptomatic treatment drugs are available for the treatment. The approved drugs for symptomatic treatment are also very few. However, only four branded drugs are available in the market. Such a concentrated market makes it difficult for diabetic neuropathy patients to afford these costly treatments that include overall management of the diabetic neuropathy where drug reimbursement or insurance is difficult. For instance, duloxetine can range from $9.00 to $54.31. Thus, the high cost of drugs used for the treatment of diabetic peripheral neuropathy may hinder the growth of the market during the forecast period.
This diabetic neuropathy drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Parent Market Analysis
Technavio categorizes the diabetic neuropathy drugs market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the diabetic neuropathy drugs market during the forecast period.
Who are the Major Diabetic Neuropathy Drugs Market Vendors?
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
- Alnylam Pharmaceuticals Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Daiichi Sankyo Co. Ltd.
- Eli Lilly and Co.
- Grunenthal GmbH
- Johnson and Johnson Inc.
- NeuroBo Pharmaceuticals Inc.
- Novartis AG
- Pfizer Inc.
This statistical study of the diabetic neuropathy drugs market encompasses successful business strategies deployed by the key vendors. The diabetic neuropathy drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
Product Insights and News
- AstraZeneca Plc - The company offers neuropathy drugs under the brand name of Bydureon.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The diabetic neuropathy drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Diabetic Neuropathy Drugs Market Value Chain Analysis
Our report provides extensive information on the value chain analysis for the diabetic neuropathy drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
- Research and development (R&D) and drug discovery
- Integration and product development
- Outbound logistics
- Marketing and sales
- Support services
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
Which are the Key Regions for Diabetic Neuropathy Drugs Market?
For more insights on the market share of various regions Request for a FREE sample now!
38% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the diabetic neuropathy drugs market in North America. Market growth in this region will be faster than the growth of the market in ROW.
The growing prevalence of diabetic neuropathy will facilitate the diabetic neuropathy drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the outbreak of COVID-19 affected all countries in North America, especially the US. It also had a slight negative impact on the diabetic neuropathy drugs market. Some scheduled treatments were either delayed or postponed. Hence, the adoption of diabetic neuropathy drugs declined slightly, which impacted the growth of the regional market in 2020 and Q1 2021 to some extent. However, the imposed restrictions by the half of 2020 may drive the market growth during the forecast period.
What are the Revenue-generating Product Segments in the Diabetic Neuropathy Drugs Market?
To gain further insights on the market contribution of various segments Request for a FREE sample
The diabetic neuropathy drugs market share growth by the calcium channel alpha-2-delta ligand segment will be significant during the forecast period. The calcium channel alpha-2-delta ligand segment includes drugs such as pregabalin (LYRICA), gabapentin (NEURONTIN), valproate sodium (Depacon), and carbamazepine (Tegretol). In December 2004, LYRICA was the second agent to be approved by the US FDA to treat neuropathic pain associated with diabetic peripheral neuropathy. Meanwhile, one alpha-2-delta medication has been licensed by the US Food and Drug Administration (FDA) for the treatment of moderate-to-severe RLS. The segment is expected to experience accelerating growth momentum during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the diabetic neuropathy drugs market size and actionable market insights on post COVID-19 impact on each segment.
You may be interested in:
Diabetic Food market - The market share has the potential to grow by USD 3.76 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 6.24%.
Diabetic Foot Ulcers Therapeutics market - The market share is expected to increase by USD 1.74 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 7.01%.
Diabetic Neuropathy Drugs Market Scope
Growth momentum & CAGR
Accelerate at a CAGR of 12.20%
Market growth 2021-2025
$ 2.37 billion
YoY growth (%)
North America, Europe, Asia, and ROW
Performing market contribution
North America at 38%
Key consumer countries
US, Canada, Germany, China, and UK
Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled
Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, and Pfizer Inc.
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
What are the Key Data Covered in this Diabetic Neuropathy Drugs Market Report?
- CAGR of the market during the forecast period 2021-2025
- Detailed information on factors that will drive diabetic neuropathy drugs market growth during the next five years
- Precise estimation of the diabetic neuropathy drugs market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the diabetic neuropathy drugs industry across North America, Europe, Asia, and ROW
- A thorough analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of diabetic neuropathy drugs market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1. Executive Summary
1.1 Market Overview
Exhibit 01: Key Finding 1
Exhibit 02: Key Finding 2
Exhibit 03: Key Finding 3
Exhibit 04: Key Finding 5
Exhibit 05: Key Finding 6
Exhibit 06: Key Finding 7
Exhibit 07: Key Finding 8
2. Market Landscape
2.1 Market ecosystem
Exhibit 08: Parent market
Exhibit 09: Market characteristics
2.2 Value chain analysis
Exhibit 10: Value chain analysis: Pharmaceuticals
2.2.1 Research and development (R&D) and drug discovery
2.2.2 Integration and product development
2.2.4 Outbound logistics
2.2.5 Marketing and sales
2.2.6 Support services
3. Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2020
3.4 Market outlook: Forecast for 2020 - 2025
3.4.1 Estimating growth rates for emerging and high-growth markets
3.4.2 Estimating growth rates for mature markets
Exhibit 13: Global - Market size and forecast 2020 - 2025 ($ million)
Exhibit 14: Global market: Year-over-year growth 2020 - 2025 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 15: Five forces analysis 2020 & 2025
4.2 Bargaining power of buyers
Exhibit 16: Bargaining power of buyers
4.3 Bargaining power of suppliers
Exhibit 17: Bargaining power of suppliers
4.4 Threat of new entrants
Exhibit 18: Threat of new entrants
4.5 Threat of substitutes
Exhibit 19: Threat of substitutes
4.6 Threat of rivalry
Exhibit 20: Threat of rivalry
4.7 Market condition
Exhibit 21: Market condition - Five forces 2020
5 Market Segmentation by Product
5.1 Market segments
Exhibit 22: Product - Market share 2020-2025 (%)
5.2 Comparison by Product
Exhibit 23: Comparison by Product
5.3 Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025
Exhibit 24: Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025 ($ million)
Exhibit 25: Calcium channel alpha-2-delta ligand - Year-over-year growth 2020-2025 (%)
5.4 SNRIs and TCAs - Market size and forecast 2020-2025
Exhibit 26: SNRIs and TCAs - Market size and forecast 2020-2025 ($ million)
Exhibit 27: SNRIs and TCAs - Year-over-year growth 2020-2025 (%)
5.5 Others - Market size and forecast 2020-2025
Exhibit 28: Others - Market size and forecast 2020-2025 ($ million)
Exhibit 29: Others - Year-over-year growth 2020-2025 (%)
5.6 Market opportunity by Product
Exhibit 30: Market opportunity by Product
6. Customer landscape
Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
Exhibit 31: ?Customer landscape?
7. Geographic Landscape
7.1 Geographic segmentation
Exhibit 32: Market share by geography 2020-2025 (%)
7.2 Geographic comparison
Exhibit 33: Geographic comparison
7.3 North America - Market size and forecast 2020-2025
Exhibit 34: North America - Market size and forecast 2020-2025 ($ million)
Exhibit 35: North America - Year-over-year growth 2020-2025 (%)
7.4 Europe - Market size and forecast 2020-2025
Exhibit 36: Europe - Market size and forecast 2020-2025 ($ million)
Exhibit 37: Europe - Year-over-year growth 2020-2025 (%)
7.5 Europe - Market size and forecast 2020-2025
Exhibit 38: Europe - Market size and forecast 2020-2025 ($ million)
Exhibit 39: Europe - Year-over-year growth 2020-2025 (%)
7.6 ROW - Market size and forecast 2020-2025
Exhibit 40: ROW - Market size and forecast 2020-2025 ($ million)
Exhibit 41: ROW - Year-over-year growth 2020-2025 (%)
7.7 Key leading countries
Exhibit 42: Key leading countries
7.8 Market opportunity by geography
Exhibit 43: Market opportunity by geography
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 Increasing prevalence of diabetic neuropathy
8.1.2 New drug approvals and strong drug pipeline
8.1.3 Rising awareness about diabetic neuropathy
8.2 Market challenges
8.2.1 High cost of treatment
8.2.2 Side-effects of major drugs
8.2.3 Reimbursement challenges
Exhibit 44: Impact of drivers and challenges
8.3 Market trends
8.3.1 Development of topical patches for the treatment of diabetic neuropathy
8.3.2 Development of digital tools for management of diabetic neuropathy
8.3.3 Association between obesity and endocrine disorders
8.3.4 Growing focus on emerging economies
9. Vendor Landscape
Exhibit 45: Vendor landscape
The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.
9.2 Landscape disruption
Exhibit 46: ?Landscape disruption?
Exhibit 47: Industry risks
9.3 Competitive landscape
10. Vendor Analysis
10.1 Vendors covered
Exhibit 48: Vendors covered
10.2 Market positioning of vendors
Exhibit 49: ?Market positioning of vendors?
10.3 Alnylam Pharmaceuticals Inc.
Exhibit 50: Alnylam Pharmaceuticals Inc. - Overview
Exhibit 51: Alnylam Pharmaceuticals Inc. - Product and service
Exhibit 52: Alnylam Pharmaceuticals Inc. - Key offerings
10.4 Astellas Pharma Inc.
Exhibit 53: Astellas Pharma Inc. - Overview
Exhibit 54: Astellas Pharma Inc. - Product and service
Exhibit 55: Astellas Pharma Inc. - Key offerings
10.5 AstraZeneca Plc
Exhibit 56: AstraZeneca Plc - Overview
Exhibit 57: AstraZeneca Plc - Product and service
Exhibit 58: AstraZeneca Plc - Key offerings
10.6 Daiichi Sankyo Co. Ltd.
Exhibit 59: Daiichi Sankyo Co. Ltd. - Overview
Exhibit 60: Daiichi Sankyo Co. Ltd. - Business segments
Exhibit 61: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibit 62: Daiichi Sankyo Co. Ltd. - Segment focus
10.7 Eli Lilly and Co.
Exhibit 63: Eli Lilly and Co. - Overview
Exhibit 64: Eli Lilly and Co. - Business segments
Exhibit 65: Eli Lilly and Co. - Key offerings
10.8 Grunenthal GmbH
Exhibit 66: Grunenthal GmbH - Overview
Exhibit 67: Grunenthal GmbH - Product and service
Exhibit 68: Grunenthal GmbH - Key offerings
10.9 Johnson and Johnson Inc.
Exhibit 69: Johnson and Johnson Inc. - Overview
Exhibit 70: Johnson and Johnson Inc. - Business segments
Exhibit 71: Johnson and Johnson Inc. - Key offerings
Exhibit 72: Johnson and Johnson Inc. - Segment focus
10.10 NeuroBo Pharmaceuticals Inc.
Exhibit 73: NeuroBo Pharmaceuticals Inc. - Overview
Exhibit 74: NeuroBo Pharmaceuticals Inc. - Product and service
Exhibit 75: NeuroBo Pharmaceuticals Inc. - Key offerings
10.11 Novartis AG
Exhibit 76: Novartis AG - Overview
Exhibit 77: Novartis AG - Business segments
Exhibit 78: Novartis AG - Key offerings
Exhibit 79: Novartis AG - Segment focus
10.12 Pfizer Inc.
Exhibit 80: Pfizer Inc. - Overview
Exhibit 81: Pfizer Inc. - Business segments
Exhibit 82: Pfizer Inc. - Key offerings
11.1 Scope of the report
11.1.1 ????Market definition
11.1.3 ????Notes and caveats
11.2 Currency conversion rates for US$
Exhibit 83: ?Currency conversion rates for US$?
11.3 Research Methodology
Exhibit 84: ?Research Methodology
Exhibit 85: ??Validation techniques employed for market sizing?
Exhibit 86: ??Information sources
11.4 List of abbreviations
Exhibit 87: List of abbreviations
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get your sample now!
Frequently Asked Questions?
- Increasing prevalence of diabetic neuropathy
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
One user only.
Quick & easy download option
Unlimited user access (Within your organization)
Complimentary Customization Included
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Did you know?
Did you know?
Did you know?
Customized Report as per your Business Needs
- Our analysts will work directly with you and understand your needs
- Get data on specified regions or segments, competitor and Vendors
- Data will be formatted and presented as per your requirements
- We offer $1000 worth of FREE customization at the time of purchase
Let us help you make report more suited to your requirements.
- Get a competitive breakdown as per your niche industry
- Customize the data with various metrics that meet your business prerequisite
- Understand Revenue Sources, Customers and many more
- Details on Market Share
- These customizations are done in a short amount of time by our analysts and industry experts